Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin 
Welcome,         Profile    Billing    Logout  
 7 Diseases   4 Trials   4 Trials   44 News 


«123
  • ||||||||||  Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
    Enrollment closed, Viral vector:  A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) -  May 3, 2020   
    P2,  N=10, Active, not recruiting, 
    NCT01560182, https://clinicaltrials.gov/ct2/show/NCT01560182; EudraCT # 2009-017349-77 Trial 2: OTL-200-c: A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD); NCT03392987, https://clinicaltrials.gov/ct2/show/NCT03392987 Recruiting --> Active, not recruiting
  • ||||||||||  Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
    Phase classification, Enrollment change, Trial primary completion date, Gene therapy:  TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) -  Dec 20, 2018   
    P1/2,  N=20, Active, not recruiting, 
    NCT01560182, https://clinicaltrials.gov/ct2/show/NCT01560182; EudraCT # 2009-017349-77 Trial 2: OTL-200-c: A Safety and Efficacy Study of Cryopreserved OTL-200 for Treatment of Metachromatic Leukodystrophy (MLD); NCT03392987, https://clinicaltrials.gov/ct2/show/NCT03392987 Phase classification: P2 --> P1/2 | N=14 --> 20 | Trial primary completion date: Apr 2023 --> Apr 2018
  • ||||||||||  Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
    Phase classification, Enrollment change, Trial primary completion date, Gene therapy:  TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) -  Mar 24, 2017   
    P2,  N=14, Active, not recruiting, 
    Phase classification: P3 --> P2 Phase classification: P1/2 --> P2 | N=20 --> 14 | Trial primary completion date: Apr 2018 --> Apr 2023
  • ||||||||||  Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
    Enrollment closed, Trial primary completion date, Gene therapy:  TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) -  Apr 21, 2015   
    P1/2,  N=20, Active, not recruiting, 
    Phase classification: P1/2 --> P2 | N=20 --> 14 | Trial primary completion date: Apr 2018 --> Apr 2023 Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018
  • ||||||||||  Lenmeldy (atidarsagene autotemcel) / Kyowa Kirin
    Enrollment status, Trial primary completion date, Gene therapy:  TIGET-MLD: Gene Therapy for Metachromatic Leukodystrophy (MLD) (clinicaltrials.gov) -  Dec 9, 2014   
    P1/2,  N=20, Enrolling by invitation, 
    Enrolling by invitation --> Active, not recruiting | Trial primary completion date: Oct 2017 --> Apr 2018 Recruiting --> Enrolling by invitation | Trial primary completion date: Dec 2015 --> Oct 2017